论文部分内容阅读
目的:探讨低位直肠癌术前采取放化疗辅助治疗措施的作用。方法:2010年7月-2015年12月在金华市中心医院治疗的120例低位直肠癌患者纳入研究,术前给予放化疗的60例患者设定为观察组,术前仅给予化疗的60例患者设定为对照组。观察比较两组的疗效、保肛率、肿瘤消退分级、凋亡指数以及不良反应。结果:观察组的肿瘤缓解总有效率78.33%明显高于对照组的46.67%(P<0.05);观察组的保肛率76.67%明显高于对照组的48.33%(P<0.05);观察组的肿瘤消退分级TRG1人数明显多于对照组、TRG2人数相当、TRG3人数明显少于对照组(P<0.05);观察组的凋亡指数明显高于对照组(P<0.05),观察组的腹泻及皮肤损伤概率均明显大于对照组(P<0.05),但其他不良反应比较差异无统计学意义(P>0.05)。结论:新辅助放化疗低位直肠癌能够提高肿瘤缓解率、保肛率,促进肿瘤消退和癌细胞凋亡,且不明显增加严重不良反应,适于临床广泛应用。
Objective: To investigate the effect of preoperative chemoradiotherapy adjuvant therapy for low rectal cancer. Methods: From July 2010 to December 2015, 120 patients with low rectal cancer who were treated in Jinhua Central Hospital were enrolled. Sixty patients who underwent chemoradiation before operation were enrolled in the observation group. Only 60 patients were given chemotherapy before operation Patients were set as control group. The curative effect, anal sphincter rate, tumor regression grade, apoptosis index and adverse reactions were compared between the two groups. Results: The total effective rate of tumor remission in observation group was significantly higher than that in control group (78.33% vs. 46.67%, P <0.05). The anal sphincter preservation rate in observation group was significantly higher than that in control group (76.67% vs 48.33%, P <0.05) (P <0.05). The apoptotic index of observation group was significantly higher than that of control group (P <0.05), and the number of TRG2 in observation group was significantly lower than that of control group (P <0.05). However, there was no significant difference in other adverse reactions between the two groups (P> 0.05). Conclusion: The neoadjuvant chemoradiation chemotherapy for rectal cancer can improve the remission rate, anal sphincter rate, promote tumor regression and cancer cell apoptosis, and does not significantly increase the serious adverse reactions, suitable for clinical application.